Filter Results
Filter Results
Filter by Modality
Allogeneic (38) Autologous (44) Bioconjugates/ADC (17) Exosomes (17) Expression Technologies (85) iPSCs (31) Mammalian (97) Microbial (19) mRNA (15) Parenteral Drug Product (52) Small Molecules (187) Viral Vectors (49)
Antibody Drug Conjugates (28) Bioavailability Enhancement (80) Bispecific Antibody (71) Difficult to Express Proteins (50) Drug device combinations (1) Drug Substance (API/HPAPI) (66) Enhanced ADCC (12) Fabs, Fusion, Scaffold and other Recombinant Proteins (29) Inhalation (34) Injectables (5) Lipid Nanoparticle Encapsulation (4) Monoclonal Antibody (88) Oral Drug Products (89) Particle Engineering (48) Solid Form Services (13)
Analytical Development (62) Antibody Humanization & Deimmunization (5) API Services (38) Bispecific DNA-to-IND (14) Cell Line Development (65) Clinical Supply Services (53) Commercial Supply Services (37) Early De-risking & Optimization (47) Fabs and Fc-Fusion proteins DNA-to-IND (2) First-in-Human Services (55) Formulation Development and Optimization (83) Ibex® Dedicate (3) Immunogenicity Assessment (11) IND-to-BLA (18) mAb DNA-to-IND: Ibex® Design (12) Manufacturing: cGMP (53) Manufacturing: GMP Drug Product (20) Manufacturing: GMP Drug Substance (38) Manufacturing: Non-GMP Manufacture (4) Parenteral Drug Product Development (12) PBPK Modeling (11) Process Development and Optimization (78) Regulatory Services (31) Scaffolds and Other Recombinant Proteins DNA-to-IND (2) Solid Form Services (5) Special Analytical Services (1) Strain Development (7) Tech Transfer (7) Tissue Acquisition (6) Viral Vector Expression Technologies (18)
4D-Nucleofector LV (4) bYlok™ Bispecific Antibodies Technology (16) Cocoon® Platform (26) GS Discovery® (11) GS Effex® (13) GS Gene Expression System® (49) GS piggyBac® Transposon System (45) GS Xceed® Gene Expression System (51) GSquad® Vectors (30) Hot Melt Extrusion (27) LNP (4) Mammalian Expression Technologies (65) Microbial Expression Technologies (19) Micro-dosing/Powder-in-capsule (14) Micronization (16) MODA® (5) Modified and Delayed Release (9) Particle Size Reduction (27) Spray Dried Dispersions (54) Taste-masking and Multiparticulates (12) Technology Selection (19) Viral Vector Expression Technologies (18) XS Technologies® (8)
Article (65) CDMO Notes Blog post (6) e-book (15) Interview (6) Peer-reviewed publication (52) Podcast (39) Poster (33) Presentation (on-demand) (31) Presentation (slides) (13) R&D Blog post (22) Report (1) Technical/Service brief (41) Video (19) Webinar (on-demand) (145) White paper (97)
   Loading...
Showing 1‐28 of 500
Technical/Service brief
5 min read
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose with enhanced...
Technical/Service brief
XS Technologies® Microbial Platform for Protein Expression Brochure
XS Technologies® are the microbial expression systems for today’s therapeutics. While achieving yields of up to 20 g/L for simple proteins and up to 12 g/L for more complex proteins, they merge simplicity and scalability. XS Technologies® Ex...
Article
5 min read
Navigating the Future of Bioconjugates and ADCs: An Expert Q&A with Iwan Bertholjotti
Webinar (on-demand)
60 min read
Unlock the future of drug development with PBBM and solid form screening for early-phase success
Struggling with poor bioavailability in your early-phase drug candidates? You're not alone. Low aqueous solubility is a common hurdle, delaying critical First-in-Human (FIH) trials and inflating costs. But what if you could accelerate development...
Article
10 min read
Empowering smarter decisions in drug development through modeling, AI and scientific expertise
Webinar (on-demand)
52 min read
Building Better Biologics: Early strategies for optimizing the progression of biotherapeutic candidates to first in human studies and beyond
The early stages of biologic drug development are critical to long-term clinical and commercial success. As biologics become more complex, an integrated approach to candidate selection, preclinical evaluation, and manufacturing readiness is essential. Th...
Poster
3 min read
Cocoon® platform demonstrates compatibility with off-the-shelf process analytical technologies
The Lonza Cocoon® Platform uniquely addresses the challenges of automated cell therapy manufacturing by enabling at-line integration of a variety of complementary systems such as Process Analytical Technologies (PAT) and electroporation. The integration o...
Poster
3 min read
End-to-end production of t cells on the Cocoon® platform, using buoyancy-activated cell sorting (bacs) for direct isolation from leukopaks
High-purity, viable T cell isolation is essential for consistent upstream processing of CAR-T cell manufacturing. Traditional magnetic cell separation uses positive or negative selection; the latter preserves cell integrity by avoiding activation and rece...
Technical/Service brief
10 min read
Elevate expression with the GSquad® Pro vector system
At Lonza, we continually invest in innovation covering all platform elements to help ensure that we keep one step ahead of the output from drug discovery groups. To ensure that the genetic instructions delivered into CHO cells at transfection can leverage...
Technical/Service brief
5 min read
Room to Grow: Exploring the Capabilities of 15,000L Microbial Manufacturing
Scaling microbial processes requires more than capacity - it demands precision, flexibility, and deep technical insight. This brochure introduces you to Lonza’s 15,000L microbial fermentation facility in Visp, Switzerland - one of the few of its kind glob...
White paper
10 min read
Industry-backed, data-driven approaches to enhancing container closure integrity
Container closure integrity (CCI) is central to ensuring product quality and patient safety. Our science- and risk-based approach integrates CCI across the full product lifecycle, from development to distribution. This white paper outlines how w...
Technical/Service brief
5 min read
Rapid Cocoon® CAR-T: rapid manufacturing of CAR-T cells with integrated selection in the Cocoon® platform
Integrated magnetic separation capabilities enrich for a pure T cell input To enable rapid manufacturing (RM) of CAR-T cells, an upstream T cell selection step is often preferred to ensure generation of a high-purity product. The Lonza Cocoon® Platform...
Presentation (on-demand)
26 min read
Overcoming biotherapeutic protein expression challenges with advanced vector technology for a range of multi-gene and difficult to express proteins
The development of biotherapeutic products is complex and the growing prevalence of next-generation and difficult-to-express formats places increasing demands on CHO expression systems to deliver high yield, scalable, and quality-consistent bioproduction....
Webinar (on-demand)
Dry powder for intranasal delivery
This webinar is your chance to get ahead in the world of drug delivery. We're talking about intranasal dry powders—a game-changer that's set to transform how we administer medicine. If you're looking for the next big thing in pharmaceutical...
Webinar (on-demand)
Industrialization of AAV manufacturing with Xcite® transient and stable production platforms
In this presentation, industry experts Suparna Sanyal and Peng Wang from Lonza take you deep into the industrialization of AAV (Adeno-Associated Virus) manufacturing. The session explores two powerful production platforms—Xcite® Transient Transfection and...
Article
10 min read
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand innovative solutions. At Lonza Advanced Synthesis the continuous flow process is integrated into early phase development, allowing for optimization of chemica...
Poster
Adeno-associated virus characterization using nanopore long read sequencing and analysis
Recombinant adeno-associated virus (rAAV) has become a leading vector for in vivo gene delivery. The quality of the AAV product is crucial for the success of gene therapy, and thorough understanding of the viral genome sequence is becoming essential for e...
Poster
3 min read
Development of high-performing stable producer cell lines for therapeutic AAV vector manufacturing
Attributed to their safety profiles and transduction efficiencies, recombinant Adeno-associated virus (AAV) vectors are widely used for treatment of human genetic diseases. However, the high cost and low productivity in AAV vector manufacturing process limit the clinical and commercial development of these life-changing therapies for more patients. Recently, we reported the development of high-performing, HEK293 cell based, helper virus-free AAV stable producer cell lines (PCL) that significantly increased the AAV productivity (>...
Poster
3 min read
Designing a Plug-and-Play System to Produce Engineered Extracellular Vesicles
Extracellular vesicles (EVs), including exosomes, are being studied extensively and have emerged as a promising novel technology for the delivery of complex therapeutic payloads such as nucleic acids or proteins. EVs are naturally occurring within the bod...
Poster
5 min read
Plasmid Engineering and Process Development to Improve Self-Complementary AAV Productivity
Self-complementary AAV (scAAV) vectors were developed by mutating one of the ITRs to form double-stranded genome. Unlike traditional single-stranded AAVs (ssAAV), scAAVs can enhance gene expression efficiency by bypassing the need for second-strand synthe...
Poster
5 min read
Large-Scale High Titer Lentiviral Production Using Lonza's Suspension Transient Transfection Platform
Lentivirus vector (LVV) is a major player in cell and gene therapies. It efficiently transduces both dividing and non-dividing cells and is able to incorporate large transgenes, making it a versatile viral vector for a number of applications where gene de...
Interview
10 min read
Q&A on large-scale commercial expansion at Lonza's Stein facility
Are you a biopharmaceutical or biotech professional looking to stay ahead in the industry? Download our comprehensive Q&A-style interview to gain exclusive insights into our significant capacity expansion at our Stein, Switzerland facility. What's Inside...
Poster
5 min read
Novel synthetic production phase promoter for enhanced titre, product quality and expression stability in CHO cells
In this scientific poster, we demonstrate the development of a novel synthetic gene promoter designed for CHO cells. Available as part of the GSquad® Pro vector system, the promoter demonstrates desirable bioproduction characteristics compared to the CMV ...
Technical/Service brief
10 min read
Novel synthetic fusion promoter for improved GS-CHO expression of biotherapeutics
Historically, advancements in CHO-based recombinant protein production have been driven predominantly by process development, and whilst these efforts have delivered significant gains, they have also highlighted a need to optimize additional process input...
White paper
15 min read
Navigating the development of dry powder for inhalation
Interest in pulmonary/nasal routes for local delivery has significantly increased over the last decade owing to challenges faced in the delivery of molecules with poor solubility, systemic side effects, or new modalities such as biologics. This increasing...
Article
10 min read
Optimizing expression vectors for biotherapeutic protein production: design principles, titer-influencing factors and promoters
The efficient production of biotherapeutic proteins hinges on the design and optimization of expression vectors. This article explores the key principles underlying vector design for maximizing protein yield, stability, and functionality in recombinant sy...
White paper
5 min read
Innovations in linking rational design and material-sparing strategies for enabled intermediates and their drug products
Did you catch our insightful webinar on Linking rational design and material-sparing strategies for enabled intermediates and their drug products? If not, or if you're looking for a concise recap of the key discussions, our new executive summary paper is ...
Presentation (on-demand)
23 min read
Challenging your AAV productivity and packaging efficiencies through a validated platform
AAV transient and stable cell line platforms represent a leap into next-generation technologies that are set to drive gene therapy commercialization. Selecting the right manufacturing approach for AAV production is key to meeting productivity and scalabil...